Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cara Therapeutics (CARA)

Cara Therapeutics (CARA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 434,087
  • Shares Outstanding, K 53,591
  • Annual Sales, $ 23,030 K
  • Annual Income, $ -88,440 K
  • 60-Month Beta 1.22
  • Price/Sales 19.25
  • Price/Cash Flow N/A
  • Price/Book 2.17
Trade CARA with:

Options Overview Details

View History
  • Implied Volatility 96.66% ( +24.00%)
  • Historical Volatility 97.52%
  • IV Percentile 90%
  • IV Rank 28.98%
  • IV High 201.67% on 08/16/21
  • IV Low 53.81% on 06/16/21
  • Put/Call Vol Ratio 0.01
  • Today's Volume 350
  • Volume Avg (30-Day) 134
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 6,120
  • Open Int (30-Day) 10,277

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.27
  • Number of Estimates 5
  • High Estimate -0.20
  • Low Estimate -0.31
  • Prior Year -0.61
  • Growth Rate Est. (year over year) +55.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.40 +8.24%
on 05/09/22
10.50 -23.71%
on 04/27/22
-2.50 (-23.79%)
since 04/26/22
3-Month
7.40 +8.24%
on 05/09/22
13.97 -42.64%
on 04/18/22
-2.45 (-23.42%)
since 02/25/22
52-Week
7.40 +8.24%
on 05/09/22
18.93 -57.69%
on 11/09/21
-5.59 (-41.10%)
since 05/26/21

Most Recent Stories

More News
Cara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates

Cara (CARA) delivered earnings and revenue surprises of 7.14% and 69.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CARA : 8.01 (-1.11%)
INBX : 12.87 (+2.39%)
Cara Therapeutics Reports First Quarter 2022 Financial Results

KORSUVA™ (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation Kapruvia® (difelikefalin) approved by...

CARA : 8.01 (-1.11%)
Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of 0% and 6.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

VCEL : 26.74 (-0.71%)
CARA : 8.01 (-1.11%)
Cara Therapeutics to Present at May Investor Conferences

STAMFORD, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a...

CARA : 8.01 (-1.11%)
Cara Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022

STAMFORD, Conn., April 29, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a...

CARA : 8.01 (-1.11%)
First Week of CARA November 18th Options Trading

Investors in Cara Therapeutics Inc saw new options begin trading this week, for the November 18th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the...

CARA : 8.01 (-1.11%)
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients

First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patientsFirst launches in Europe...

CARA : 8.01 (-1.11%)
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients

Regulatory News:

CARA : 8.01 (-1.11%)
Relative Strength Alert For Cara Therapeutics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

CARA : 8.01 (-1.11%)
UnitedHealth (UNH) to Post Q1 Earnings: What to Expect

UnitedHealth Group's (UNH) first-quarter results are likely to reflect the benefits of improving premiums and products.

UNH : 502.23 (+0.83%)
UTHR : 224.78 (-1.58%)
CARA : 8.01 (-1.11%)
CLOV : 2.66 (+3.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States.

See More

Key Turning Points

3rd Resistance Point 8.53
2nd Resistance Point 8.36
1st Resistance Point 8.23
Last Price 8.01
1st Support Level 7.93
2nd Support Level 7.76
3rd Support Level 7.63

See More

52-Week High 18.93
Fibonacci 61.8% 14.53
Fibonacci 50% 13.16
Fibonacci 38.2% 11.80
Last Price 8.01
52-Week Low 7.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar